JP2023548973A5 - - Google Patents
Info
- Publication number
- JP2023548973A5 JP2023548973A5 JP2023552149A JP2023552149A JP2023548973A5 JP 2023548973 A5 JP2023548973 A5 JP 2023548973A5 JP 2023552149 A JP2023552149 A JP 2023552149A JP 2023552149 A JP2023552149 A JP 2023552149A JP 2023548973 A5 JP2023548973 A5 JP 2023548973A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- membrane protein
- type
- target membrane
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110619P | 2020-11-06 | 2020-11-06 | |
| US63/110,619 | 2020-11-06 | ||
| PCT/US2021/058291 WO2022099038A1 (en) | 2020-11-06 | 2021-11-05 | Membrane protein targeting engineered deubiquitinases and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548973A JP2023548973A (ja) | 2023-11-21 |
| JP2023548973A5 true JP2023548973A5 (cg-RX-API-DMAC7.html) | 2024-11-12 |
Family
ID=81456825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552149A Pending JP2023548973A (ja) | 2020-11-06 | 2021-11-05 | 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240002473A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4240754A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023548973A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116802198A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021373873A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200983A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022099038A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026085496A1 (en) * | 2024-10-18 | 2026-04-23 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for using engineered deubiquitinases for targeted stabilization of voltage-gated sodium channels |
| CN121471382B (zh) * | 2026-01-12 | 2026-07-24 | 合肥综合性国家科学中心大健康研究院 | 去泛素化酶Fc融合蛋白及其产品、制备方法和在苗头化合物筛选中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541074A (en) * | 1986-07-25 | 1996-07-30 | The Children's Medical Center Corporation | Antibodies to dystrophin and uses therefor |
| CN101671688A (zh) * | 2009-09-25 | 2010-03-17 | 上海大学 | EGFP融合的β2肾上腺素能受体、其重组表达载体及其构建方法 |
| EP3706782A4 (en) * | 2017-11-06 | 2021-09-08 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES |
| WO2019126762A2 (en) * | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| EP3793689A1 (en) * | 2018-05-15 | 2021-03-24 | Translate Bio, Inc. | Subcutaneous delivery of messenger rna |
-
2021
- 2021-11-05 CA CA3200983A patent/CA3200983A1/en active Pending
- 2021-11-05 JP JP2023552149A patent/JP2023548973A/ja active Pending
- 2021-11-05 EP EP21890169.2A patent/EP4240754A4/en active Pending
- 2021-11-05 WO PCT/US2021/058291 patent/WO2022099038A1/en not_active Ceased
- 2021-11-05 US US18/251,848 patent/US20240002473A1/en active Pending
- 2021-11-05 AU AU2021373873A patent/AU2021373873A1/en active Pending
- 2021-11-05 CN CN202180089134.3A patent/CN116802198A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250276000A1 (en) | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | |
| JP6472784B2 (ja) | 細胞内在化を誘導するためのcd20結合免疫毒素及びそれを用いる方法 | |
| JP2020096630A5 (cg-RX-API-DMAC7.html) | ||
| CN111132999A (zh) | 支架蛋白 | |
| CN110157738B (zh) | 靶向cd19和cd22的工程化免疫细胞及其应用 | |
| WO2023057946A1 (en) | Serum half-life extended pd-l1 binding polypeptides | |
| CN119955743A (zh) | 修饰的溶瘤病毒、其组合物和用途 | |
| US20240358797A1 (en) | Oncoselective cancer therapy | |
| WO2025082038A1 (zh) | 靶向保守的HIV gp41亚基近膜端外区的重组干扰素药物及其应用 | |
| CN117980465A (zh) | 一种用于艾滋病病毒感染基因治疗的基因序列构建体 | |
| KR102651002B1 (ko) | 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물 | |
| US20260132180A1 (en) | Oncoselective therapy | |
| JP2023549761A5 (cg-RX-API-DMAC7.html) | ||
| AU2023307937A1 (en) | Encrypted rna and methods of its use | |
| CN119490584B (zh) | 抗埃博拉病毒VP40蛋白的纳米抗体及其编码mRNA和应用 | |
| US20240002473A1 (en) | Membrane protein targeting engineered deubiquitinases and methods of use thereof | |
| JP2023549167A5 (cg-RX-API-DMAC7.html) | ||
| JP2023551068A5 (cg-RX-API-DMAC7.html) | ||
| KR20240165998A (ko) | Il2 면역접합체 제조 | |
| CN119317430A (zh) | 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途 | |
| AU2022339815A1 (en) | Antigen recognizing receptors targeting dll3 and uses thereof | |
| EP4520768A1 (en) | Vhh-ch3 fusion proteins | |
| EP4548936A1 (en) | Antibody-drug conjugates having a tailor-made drug-to-antibody ratio | |
| CN120718913A (zh) | 编码双特异性抗体的治疗性多核苷酸 | |
| CN120603955A (zh) | 具有工程化功能的病毒载体及其生产方法 |